


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+0.33%
+0.33%
+0.06%
+0.93%
+1.21%
BNTX
BioNTech
$95.37
Strengths

Upgraded on attractively valued

Earnings are forecast to grow
BNTX Price Performance
$102.7 (-7.14%)
$98.62 (-3.30%)
$110.03 (-13.32%)
$122.85 (-22.37%)
BNTX has Fair risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

BNTX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
BNTX Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
BNTX Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
EXEL
46.61
+0.26%
CRSP
56.23
-0.49%
BIIB
176.44
+0.93%
AMGN
333.06
+0.47%
What is BNTX current stock price?
What are BNTX stock strengths?
What is BNTX Risk Level?
What is BNTX market cap and volume?
What is BNTX current Stock IQ?
Should I buy BNTX stock right now?
Is BNTX a Strong Buy right now?
What does a 'Strong Buy' rating mean for BNTX?
What does a 'Strong Sell' rating mean for BNTX?
What factors influence BNTX's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+0.33%
+0.33%
+0.06%
+0.93%
+1.21%
BNTX
BioNTech
Current Price
$95.37
Stock Insights
Strengths

Upgraded on attractively valued

Earnings are forecast to grow
Linked to BNTX
EXEL
46.61
+0.26%
CRSP
56.23
-0.49%
BIIB
176.44
+0.93%
AMGN
333.06
+0.47%

BNTX Price Performance
$102.7 (-7.14%)
$98.62 (-3.30%)
$110.03 (-13.32%)
$122.85 (-22.37%)
BNTX Analysts Opinion
BNTX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
BNTX Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
BNTX Street Sentiment is extremely bullish and have positive views on the near-term outlook
BNTX has Fair risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Average key support and resistance price levels
BNTX Stock IQ
BNTX Latest Analysis
BioNTech SE (BNTX) Closes the Acquisition of CureVac N.V.. BioNTech SE (NASDAQ:BNTX) is one of the Stocks That Will Go To The Moon in 2026. On December 18 BioNTech SE (NASDAQ:BNTX) announced the closing of its acquisition of CureVac N.V. (NASDAQ:CVAC) which is another mRNA-focused biotech firm from Mainz Germany. Management noted that the deal had closed after the expiration of the subsequent offering [….]
Tue Dec 23, 2025
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field. MAINZ Germany December 18 2025 – (Nasdaq: BNTX BioNTech or the Company) today announced the closing of its acquisition of CureVac N.V. (Nasdaq: CVAC CureVac) and that the subsequent offering period (the Subsequent Offering Period) of the exchange offer (the Offer) for all outstanding shares of CureVac expired today at 12:01 a.m. Eastern Time. With the successful
Thu Dec 18, 2025
BioNTech SE (BNTX) is a Buy on Lung Cancer Treatment Prospects: Clear Street. BioNTech SE (NASDAQ:BNTX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8 Clear Street analysts reiterated a Buy rating on BioNTech SE (NASDAQ:BNTX) buoyed by top-line results on one of the companys experimental treatments. Gotistobart is the companys anti-CTLA4 therapy in second-line or later squamous non-small cell [….]
Thu Dec 11, 2025
BioNTech: Maintaining Strong Buy After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart.
Tue Dec 9, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
BNTX Stock trends
BNTX Stock performance
BNTX Stock analysis
BNTX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.